Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
View Patent ↗The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
1. A method of treating heart failure comprising:
(a) identifying a patient having heart failure; and
(b) administering to said patient a histone deacetylase inhibitor.
2. The method of claim 1 , wherein said histone deacetylase inhibitor is selected from the group consisting of trichostatin A, trapoxin B, MS 275-27, m-carboxycinnamic acid bis-hydroxamide, depudecin, oxamfiatin, apicidin, suberoylanilide hydroxamic acid, Scriptaid, pyroxamide, 2-amino-8-oxo-9,10-epoxy-decanoyl, 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamide and FR901228.
3. The method of claim 1 , wherein administering comprises intravenous administration of said histone deacetylase inhibitor.
4. The method of claim 1 , wherein administering comprises oral, transdermal, sustained release, suppository, or sublingual administration.
5. The method of claim 1 , further comprising administering to said patient a second therapeutic regimen.
6. The method of claim 5 wherein said second therapeutic regimen is selected from the group consisting of a beta blocker, an iontrope, diuretic, ACE-I, AII antagonist, and Ca ++ -blocker.
7. The method of claim 5 , wherein said second therapeutic regimen is administered at the same time as said histone deacetylase inhibitor.
8. The method of claim 5 , wherein said second therapeutic regimen is administered either before or after said histone deacetylase inhibitor.
9. The method of claim 1 , wherein treating comprises improving one or more symptoms of heart failure.
10. The method of claim 9 , wherein said one or more symptoms comprises increased exercise capacity, increased blood ejection volume, left ventricular end diastolic pressure, pulmonary capillary wedge pressure, cardiac output, cardiac index, pulmonary artery pressures, left ventricular end systolic and diastolic dimensions, left and right ventricular wall stress, or wall tension, quality of life, disease-related morbidity and mortality.